Search NASA⌕ Search

SEARCH · Search NASA

Results for “Phase 2”

Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 235 records · Page 13
All sourcesNASA NTRSDOE OSTI
DOE OSTI2017

IDC Re-Engineering Phase 2 System Specification Document Version 1.5

This document contains the system specifications derived to satisfy the system requirements found in the IDC System Requirements Document for the IDC Re-Engineering Phase 2 project. This System Specification Document (SSD) defines waveform data processing requirements for the International Data Centre (IDC) of the Comprehensive Nuclear Test Ban Treaty Organization (CTBTO). The routine processing includes characterization of events with the objective of screening out events considered to be consistent with natural phenomena or non-nuclear, man-made phenomena. This document does not address requirements concerning acquisition, processing and analysis of radionuclide data but does include requirements for the dissemination of radionuclide data and products.

97 MATHEMATICS AND COMPUTING↗
DOE OSTI2016

Short-Course Hypofractionated Radiation Therapy With Boost in Women With Stages 0 to IIIa Breast Cancer: A Phase 2 Trial

Purpose: Conventionally fractionated whole-breast irradiation (WBI) with a boost takes approximately 6 to 7 weeks. We evaluated a short course of hypofractionated (HF), accelerated WBI in which therapy was completed in 3 weeks inclusive of a sequential boost. Methods and Materials: We delivered a whole-breast dose of 36.63 Gy in 11 fractions of 3.33 Gy over 11 days, followed by a lumpectomy bed boost in 4 fractions of 3.33 Gy delivered once daily for a total of 15 treatment days. Acute toxicities were scored using Common Terminology Criteria for Adverse Events version 4. Late toxicities were scored using the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer scale. Cosmesis was scored using the Harvard Cosmesis Scale. Our primary endpoint was freedom from locoregional failure; we incorporated early stopping criteria based on predefined toxicity thresholds. Cosmesis was examined as a secondary endpoint. Results: We enrolled 83 women with stages 0 to IIIa breast cancer. After a median follow-up of 40 months, 2 cases of isolated ipsilateral breast tumor recurrence occurred (2 of 83; crude rate, 2.4%). Three-year estimated local recurrence-free survival was 95.9% (95% confidence interval [CI]: 87.8%-98.7%). The 3-year estimated distant recurrence-free survival was 97.3% (95% CI: 89.8%-99.3%). Three-year secondary malignancy-free survival was 94.3% (95% CI: 85.3%-97.8%). Twenty-nine patients (34%) had grade 2 acute toxicity, and 1 patient had a late grade 2 toxicity (fibrosis). One patient had acute grade 3 dermatitis, whereas 2 patients experienced grade 3 late skin toxicity. Ninety-four percent of evaluable patients had good or excellent cosmesis. Conclusions: Our phase 2 institutional study offers one of the shortest courses of HF therapy, delivered in 15 fractions inclusive of a sequential boost. We demonstrated expected low toxicity and high local control rates with good to excellent cosmetic outcomes. This fractionation scheme is feasible and well tolerated and offers women WBI in a highly convenient schedule.

62 RADIOLOGY AND NUCLEAR MEDICINE↗
DOE OSTI2016

Multicenter Phase 2 Study of Cisplatin and 5-Fluorouracil With Concurrent Radiation Therapy as an Organ Preservation Approach in Patients With Squamous Cell Carcinoma of the Cervical Esophagus

Purpose: To clarify, in a multicenter, single-arm, phase 2 study (UMIN Clinical Trials Registry no. UMIN000001439), the clinical profile of chemoradiotherapy (CRT) for cervical esophageal cancer. Patients and Methods: Patients with operable cervical esophageal cancer, excluding candidates for endoscopic resection, were enrolled. Protocol treatment consisted of CRT and adjuvant chemotherapy (CT). First, patients received concurrent CRT with 5-fluorouracil (5-FU) plus cisplatin (CDDP). Chemotherapy consisted of 5-FU at 700 mg/m{sup 2} intravenous on days 1 to 4 and CDDP at 70 mg/m{sup 2} intravenous on day 1, repeated every 4 weeks for 2 cycles. Radiation therapy consisted of 60 Gy in 30 fractions. After completion of CRT, 2 additional cycles of CT with 5-FU (800 mg/m{sup 2}, days 1-5) and CDDP (80 mg/m{sup 2}, day 1) were repeated at a 4-week interval. The primary endpoint was 3-year overall survival. Results: Thirty patients were enrolled across 8 institutions in Japan, consisting of 26 men and 4 women with a median age of 64.5 years (range, 50-75 years). No grade 4 hematologic toxicity was seen in the CRT phase, and 1 grade 4 thrombocytopenia was seen in the CT phase. Grade 3 nonhematologic acute toxicities in the CRT phase were nausea (10%), mucositis (13.3%), and dysphagia (13.3%). No treatment-related death in either phase occurred. Overall complete response rate was 73%, and 3-year overall and laryngectomy-free survival were 66.5% and 52.5%, respectively. Regarding T4 disease, 3-year overall and laryngectomy-free survival were 58.3% and 38.5%, respectively. Conclusions: This study, the first prospective study for cervical esophageal cancer, showed that CRT has sufficient efficacy and safety for use as an alternative to surgery for these patients.

62 RADIOLOGY AND NUCLEAR MEDICINE↗
DOE OSTI2015

Phase 2 Study of Temozolomide-Based Chemoradiation Therapy for High-Risk Low-Grade Gliomas: Preliminary Results of Radiation Therapy Oncology Group 0424

Purpose: Radiation Therapy Oncology Group (RTOG) 0424 was a phase 2 study of a high-risk low-grade glioma (LGG) population who were treated with temozolomide (TMZ) and radiation therapy (RT), and outcomes were compared to those of historical controls. This study was designed to detect a 43% increase in median survival time (MST) from 40.5 to 57.9 months and a 20% improvement in 3-year overall survival (OS) rate from 54% to 65% at a 10% significance level (1-sided) and 96% power. Methods and Materials: Patients with LGGs with 3 or more risk factors for recurrence (age ≥40 years, astrocytoma histology, bihemispherical tumor, preoperative tumor diameter of ≥6 cm, or a preoperative neurological function status of >1) were treated with RT (54 Gy in 30 fractions) and concurrent and adjuvant TMZ. Results: From 2005 to 2009, 129 evaluable patients (75 males and 54 females) were accrued. Median age was 49 years; 91% had a Zubrod score of 0 or 1; and 69%, 25%, and 6% of patients had 3, 4, and 5 risk factors, respectively. Patients had median and minimum follow-up examinations of 4.1 years and 3 years, respectively. The 3-year OS rate was 73.1% (95% confidence interval: 65.3%-80.8%), which was significantly improved compared to that of prespecified historical control values (P<.001). Median survival time has not yet been reached. Three-year progression-free survival was 59.2%. Grades 3 and 4 adverse events occurred in 43% and 10% of patients, respectively. One patient died of herpes encephalitis. Conclusions: The 3-year OS rate of 73.1% for RTOG 0424 high-risk LGG patients is higher than that reported for historical controls (P<.001) and the study-hypothesized rate of 65%.

62 RADIOLOGY AND NUCLEAR MEDICINE↗
NASA NTRS1993

NASA satellite communications application research. Phase 2: Efficient high power, solid state amplifier for EFH communications

The final report describes the work performed from 9 Jun. 1992 to 31 Jul. 1993 on the NASA Satellite Communications Application Research (SCAR) Phase 2 program, Efficient High Power, Solid State Amplifier for EHF Communications. The purpose of the program was to demonstrate the feasibility of high-efficiency, high-power, EHF solid state amplifiers that are smaller, lighter, more efficient, and less costly than existing traveling wave tube (TWT) amplifiers by combining the output power from up to several hundred solid state amplifiers using a unique orthomode spatial power combiner (OSPC).

Benet, James↗
NASA NTRS1977

Antenna evaluation study for the shuttle multispectral radar, phase 2

The results of the second phase of the Antenna Evaluation Study for the Shuttle Imaging Radar are presented. The objectives of Phase II were (1) to complete the specifications for the subarray test panels, (2) to begin a study of the effects of electrical and mechanical tolerance variations on overall SIRA performance, (3) to initiate the development of a mathematical model which adequately described the array performance and (4) to begin the development of a comprehensive computer program which will eventually simulate the performance characteristics of the antenna in a spaceborne environment. Items (2), (3), and (4) were begun in Phase I (ahead of schedule), and because of this, it has been possible to accelerate the Phase II modeling/simulation objectives to the point where simulations of expected mechanical/electrical errors have already been produced.

Coffey, E. L., III↗
DOE OSTI2013

RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Carcinoma of the Anal Canal

Purpose: A multi-institutional phase 2 trial assessed the utility of dose-painted intensity modulated radiation therapy (DP-IMRT) in reducing grade 2+ combined acute gastrointestinal and genitourinary adverse events (AEs) of 5-fluorouracil (5FU) and mitomycin-C (MMC) chemoradiation for anal cancer by at least 15% compared with the conventional radiation/5FU/MMC arm from RTOG 9811. Methods and Materials: T2-4N0-3M0 anal cancer patients received 5FU and MMC on days 1 and 29 of DP-IMRT, prescribed per stage: T2N0, 42 Gy elective nodal and 50.4 Gy anal tumor planning target volumes (PTVs) in 28 fractions; T3-4N0-3, 45 Gy elective nodal, 50.4 Gy ≤3 cm or 54 Gy >3 cm metastatic nodal and 54 Gy anal tumor PTVs in 30 fractions. The primary endpoint is described above. Planned secondary endpoints assessed all AEs and the investigator’s ability to perform DP-IMRT. Results: Of 63 accrued patients, 52 were evaluable. Tumor stage included 54% II, 25% IIIA, and 21% IIIB. In primary endpoint analysis, 77% experienced grade 2+ gastrointestinal/genitourinary acute AEs (9811 77%). There was, however, a significant reduction in acute grade 2+ hematologic, 73% (9811 85%, P=.032), grade 3+ gastrointestinal, 21% (9811 36%, P=.0082), and grade 3+ dermatologic AEs 23% (9811 49%, P<.0001) with DP-IMRT. On initial pretreatment review, 81% required DP-IMRT replanning, and final review revealed only 3 cases with normal tissue major deviations. Conclusions: Although the primary endpoint was not met, DP-IMRT was associated with significant sparing of acute grade 2+ hematologic and grade 3+ dermatologic and gastrointestinal toxicity. Although DP-IMRT proved feasible, the high pretreatment planning revision rate emphasizes the importance of real-time radiation quality assurance for IMRT trials.

62 RADIOLOGY AND NUCLEAR MEDICINE↗
DOE OSTI2014

Operation of Concentrating Solar Power Plants in the Western Wind and Solar Integration Phase 2 Study

The Western Wind and Solar Integration Study (WWSIS) explores various aspects of the challenges and impacts of integrating large amounts of wind and solar energy into the electric power system of the West. The phase 2 study (WWSIS-2) is one of the first to include dispatchable concentrating solar power (CSP) with thermal energy storage (TES) in multiple scenarios of renewable penetration and mix. As a result, it provides unique insights into CSP plant operation, grid benefits, and how CSP operation and configuration may need to change under scenarios of increased renewable penetration. Examination of the WWSIS-2 results indicates that in all scenarios, CSP plants with TES provides firm system capacity, reducing the net demand and the need for conventional thermal capacity. The plants also reduced demand during periods of short-duration, high ramping requirements that often require use of lower efficiency peaking units. Changes in CSP operation are driven largely by the presence of other solar generation, particularly PV. Use of storage by the CSP plants increases in the higher solar scenarios, with operation of the plant often shifted to later in the day. CSP operation also becomes more variable, including more frequent starts. Finally, CSP output is often very low during the day in scenarios with significant PV, which helps decrease overall renewable curtailment (over-generation). However, the configuration studied is likely not optimal for High Solar Scenario implying further analysis of CSP plant configuration is needed to understand its role in enabling high renewable scenarios in the Western United States.

14 SOLAR ENERGY↗
DOE OSTI2013

Neoadjuvant Chemoradiation for Distal Rectal Cancer: 5-Year Updated Results of a Randomized Phase 2 Study of Neoadjuvant Combined Modality Chemoradiation for Distal Rectal Cancer

Purpose: To assess the efficacy of 2 different approaches to neoadjuvant chemoradiation for distal rectal cancers. Methods and Materials: One hundred six patients with T3/T4 distal rectal cancers were randomized in a phase 2 study. Patients received either continuous venous infusion (CVI) of 5-Fluorouracil (5-FU), 225 mg/m{sup 2} per day, 7 days per week plus pelvic hyperfractionated radiation (HRT), 45.6 Gy at 1.2 Gy twice daily plus a boost of 9.6 to 14.4 Gy for T3 or T4 cancers (Arm 1), or CVI of 5-FU, 225 mg/m{sup 2} per day, Monday to Friday, plus irinotecan, 50 mg/m{sup 2} once weekly × 4, plus pelvic radiation therapy (RT), 45 Gy at 1.8 Gy per day and a boost of 5.4 Gy for T3 and 9 Gy for T4 cancers (Arm 2). Surgery was performed 4 to 10 weeks later. Results: All eligible patients (n=103) are included in this analysis; 2 ineligible patients were excluded, and 1 patient withdrew consent. Ninety-eight of 103 patients (95%) underwent resection. Four patients did not undergo surgery for either disease progression or patient refusal, and 1 patient died during induction chemotherapy. The median time of follow-up was 6.4 years in Arm 1 and 7.0 years in Arm 2. The pathological complete response (pCR) rates were 30% in Arm 1 and 26% in Arm 2. Locoregional recurrence rates were 16% in Arm 1 and 17% in Arm 2. Five-year survival rates were 61% and 75% and Disease-specific survival rates were 78% and 85% for Arm1 and Arm 2, respectively. Five second primaries occurred in patients on Arm 1, and 1 second primary occurred in Arm 2. Conclusions: High rates of disease-specific survival were seen in each arm. Overall survival appears affected by the development of unrelated second cancers. The high pCR rates with 5-FU and higher dose radiation in T4 cancers provide opportunity for increased R0 resections and improved survival.

62 RADIOLOGY AND NUCLEAR MEDICINE↗
DOE OSTI2013

Phase 2 Trial of Accelerated, Hypofractionated Whole-Breast Irradiation of 39 Gy in 13 Fractions Followed by a Tumor Bed Boost Sequentially Delivering 9 Gy in 3 Fractions in Early-Stage Breast Cancer

Purpose: To report a phase 2 trial of accelerated, hypofractionated whole-breast irradiation (AH-WBI) delivered as a daily dose of 3 Gy to the whole breast followed by a tumor bed boost. Methods and Materials: Two hundred seventy-six patients diagnosed with breast cancer (pT1-2 and pN0-1a) who had undergone breast-conserving surgery in which the operative margins were negative were treated with AH-WBI delivered as 39 Gy in 13 fractions of 3 Gy to the whole breast once daily over 5 consecutive working days, and 9 Gy in 3 sequential fractions of 3 Gy to a lumpectomy cavity, all within 3.2 weeks. Results: After a median follow-up period of 57 months (range: 27-75 months), the rate of 5-year locoregional recurrence was 1.4% (n=4), whereas that of disease-free survival was 97.4%. No grade 3 skin toxicity was reported during the follow-up period. Qualitative physician cosmetic assessments of good or excellent were noted in 82% of the patients at 2 months after the completion of AH-WBI. The global cosmetic outcome did not worsen over time, and a good or excellent cosmetic outcome was reported in 82% of the patients at 3 years. The mean pretreatment percentage breast retraction assessment was 12.00 (95% confidence interval [CI]: 11.14-12.86). The mean value of percentage breast retraction assessment increased to 13.99 (95% CI: 12.17-15.96) after 1 year and decreased to 13.54 (95% CI: 11.84-15.46) after 3 years but was not significant (P>.05). Conclusions: AH-WBI consisting of 39 Gy in 13 fractions followed by a tumor bed boost sequentially delivering 9 Gy in 3 fractions can be delivered with excellent disease control and tolerable skin toxicity in patients with early-stage breast cancer after breast-conserving surgery.

62 RADIOLOGY AND NUCLEAR MEDICINE↗
DOE OSTI2015

Beta/gamma and alpha backgrounds in CRESST-II Phase 2

The experiment CRESST-II aims at the detection of dark matter with scintillating CaWO{sub 4} crystals operated as cryogenic detectors. Recent results on spin-independent WIMP-nucleon scattering from the CRESST-II Phase 2 allowed to probe a new region of parameter space for WIMP masses below 3 GeV/c{sup 2}. This sensitivity was achieved after background levels were reduced significantly. We present extensive background studies of a CaWO{sub 4} crystal, called TUM40, grown at the Technische Universität München. The average beta/gamma rate of 3.51/[kg keV day] (1-40 keV) and the total intrinsic alpha activity from natural decay chains of 3.08±0.04 mBq/kg are the lowest reported for CaWO{sub 4} detectors. Contributions from cosmogenic activation, surface-alpha decays, external radiation and intrinsic alpha/beta emitters are investigated in detail. A Monte-Carlo based background decomposition allows to identify the origin of the majority of beta/gamma events in the energy region relevant for dark matter search.

72 PHYSICS OF ELEMENTARY PARTICLES AND FIELDS↗
NASA NTRS1998

Computational/Experimental Aeroheating Predictions for X-33: Vehicle - Phase 2

Laminar and turbulent heating-rate calculations from an "engineering" code and laminar calculations from a "benchmark" Navier-Stokes code are compared with experimental wind-tunnel data obtained on several candidate configurations for the X-33 Phase 2 flight vehicle. The experimental data were obtained at a Mach number of 6 and a freestream Reynolds number ranging from 1 to 8 x 10(exp 6)/ft. Comparisons are presented along the windward symmetry plane and in a circumferential direction around the body at several axial stations at angles of attack from 20 to 40 deg. The experimental results include both laminar and turbulent flow. For the highest angle of attack some of the measured heating data exhibited a "non-laminar" behavior which caused the heating to increase above the laminar level long before "classical" transition to turbulent flow was observed. This trend was not observed at the lower angles of attack. When the flow was laminar, both codes predicted the heating along the windward symmetry plane reasonably well but under-predicted the heating in the chine region. When the flow was turbulent the LATCH code accurately predicted the measured heating rates. Both codes were used to calculate heating rates over the X-33 vehicle at the peak heating point on the design trajectory and they were found to be in very good agreement over most of the vehicle windward surface.

Hamilton, H. Harris, II↗
NASA NTRS2011

Deep Space Habitat Team: HEFT Phase 2 Effects

HEFT was a NASA-wide team that performed analyses of architectures for human exploration beyond LEO, evaluating technical, programmatic, and budgetary issues to support decisions at the highest level of the agency in HSF planning. HEFT Phase I (April - September, 2010) and Phase II (September - December, 2010) examined a broad set of Human Exploration of Near Earth Objects (NEOs) Design Reference Missions (DRMs), evaluating such factors as elements, performance, technologies, schedule, and cost. At end of HEFT Phase 1, an architecture concept known as DRM 4a represented the best available option for a full capability NEO mission. Within DRM4a, the habitation system was provided by Deep Space Habitat (DSH), Multi-Mission Space Exploration Vehicle (MMSEV), and Crew Transfer Vehicle (CTV) pressurized elements. HEFT Phase 2 extended DRM4a, resulting in DRM4b. Scrubbed element-level functionality assumptions and mission Concepts of Operations. Habitation Team developed more detailed concepts of the DSH and the DSH/MMSEV/CTV Conops, including functionality and accommodations, mass & volume estimates, technology requirements, and DDT&E costs. DRM 5 represented an effort to reduce cost by scaling back on technologies and eliminating the need for the development of an MMSEV.

Toups, Larry D.↗
DOE OSTI2019

A Phase 2 Study of Induction Chemotherapy Using Docetaxel, Cisplatin, and S-1 for Gastric Cancer with Peritoneal Metastasis (KUGC06)

Background: The authors previously showed the significant efficacy of S-1 plus cisplatin for gastric cancer with limited peritoneal metastasis. They conducted a phase 2 study to evaluate the safety and efficacy of induction chemotherapy using a docetaxel, cisplatin, and S-1 (DCS) triplet regimen to treat gastric cancer with peritoneal metastasis. Methods: The key eligibility criteria were gastric cancer with peritoneal metastasis or positive peritoneal cytology but no other distant metastases and capability of oral administration. The patients received three 28-day cycles of DCS (60 mg/m{sup 2} of cisplatin, 40 mg/m{sup 2} of docetaxel on day 1, and 80 mg/m{sup 2} of S-1 from day 1 to day 14), then underwent D2 gastrectomy if R0 was possible. The primary end point was the R0 resection rate. The sample size was determined to have 80% power for detecting a 20% improvement in the R0 resection rate over a 45% baseline for a one-tailed alpha of 0.1. Results: Among 30 enrolled patients, 24 completed three cycles of DCS. The most frequent grade 3 or 4 toxicity was neutropenia (60%). A complete response of peritoneal metastasis was observed in 16 patients, and 14 patients achieved R0 resection (47%; 95% confidence interval 28–66%). When the extent of peritoneal metastasis was classified as P0CY1, P1, P2, and P3 according to the Japanese classification, the R0 resection rates were respectively 63%, 60%, 46% and 0%. Conclusions: Induction chemotherapy with DCS is safe and can achieve R0 resection for some patients with limited peritoneal metastasis or positive peritoneal cytology. The efficacy, however, appears similar to that of S-1 plus cisplatin.

62 RADIOLOGY AND NUCLEAR MEDICINE↗
NASA NTRS1990

NASA/DOD Aerospace Knowledge Diffusion Research Project. Paper 5: Aerospace librarians and technical information specialists as information intermediaries: A report of phase 2 activities of the NASA/DOD Aerospace Knowledge Diffusion Research Project

The flow of U.S. government-funded and foreign scientific and technical information (STI) through libraries and related facilities to users in government and industry is examined, summarizing preliminary results of Phase 2 of the NASA/DOD Aerospace Knowledge Diffusion Research Project (NAKDRP). The design and objectives of NAKDRP are reviewed; the NAKDRP model of STI transfer among producers, STI intermediaries, surrogates (technical report repositories or clearinghouses), and users is explained and illustrated with diagrams; and particular attention is given to the organization and operation of aerospace libraries. In a survey of North American libraries it was found that 25-30 percent of libraries regularly receive technical reports from ESA and the UK; the corresponding figures for Germany and for France, Sweden, and Japan are 18 and 5 percent, respectively. Also included is a series of bar graphs showing the librarians' assessments of the quality and use of NASA Technical Reports.

Pinelli, Thomas E.↗
NASA NTRS2014

Elemental Water Impact Test: Phase 2 36-Inch Aluminum Tank Head

Spacecraft are being designed based on LS-DYNA simulations of water landing impacts. The Elemental Water Impact Test (EWIT) series was undertaken to assess the accuracy of LS-DYNA water impact simulations. EWIT Phase 2 featured a 36-inch aluminum tank head. The tank head was outfitted with one accelerometer, twelve pressure transducers, three string potentiometers, and four strain gages. The tank head was dropped from heights of 1 foot and 2 feet. The focus of this report is the correlation of analytical models against test data. As a measure of prediction accuracy, peak responses from the baseline LS-DYNA model were compared to peak responses from the tests.

Vassilakos, Gregory J.↗
DOE OSTI2016

Eastern Cooperative Oncology Group and American College of Radiology Imaging Network Randomized Phase 2 Trial of Neoadjuvant Preoperative Paclitaxel/Cisplatin/Radiation Therapy (RT) or Irinotecan/Cisplatin/RT in Esophageal Adenocarcinoma: Long-Term Outcome and Implications for Trial Design

Purpose: Toxicity, pathologic complete response, and long-term outcomes are reported for the neoadjuvant therapies assessed in a randomized phase 2 Eastern Cooperative Oncology Group and American College of Radiology Imaging Network trial for operable esophageal adenocarcinoma, staged as II-IVa by endoscopy/ultrasonography (EUS). Methods and Materials: A total of 86 eligible patients began treatment. For arm A, preoperative chemotherapy was cisplatin, 30 mg/m{sup 2}, and irinotecan, 50 mg/m{sup 2}, on day 1, 8, 22, 29 during 45 Gy radiation therapy (RT), 1.8 Gy per day over 5 weeks. Adjuvant therapy was cisplatin, 30 mg/m{sup 2}, and irinotecan, 65 mg/m{sup 2} day 1, 8 every 21 days for 3 cycles. Arm B therapy was cisplatin, 30 mg/m{sup 2}, and paclitaxel, 50 mg/m{sup 2}, day 1, 8, 15, 22, 29 with RT, followed by adjuvant cisplatin, 75 mg/m{sup 2}, and paclitaxel, 175 mg/m{sup 2}, day 1 every 21 days for 3 cycles. Stratification included EUS stage and performance status. Results: In arm A, median overall survival was 35 months, and 5-, 6-, and 7-year survival rates were 46%, 39%, and 35%, respectively, whereas for arm B, they were 21 months and 27%, 27%, and 23%, respectively. Median progression- or recurrence-free survival (PFS) was 39.8 months with a 3-year PFS of 50% for arm A and 12.4 months (P=.046) with 3-year PFS of 28% for arm B. Eighty percent of the observed incidents of progression occurred within 19 months. Survival did not differ significantly by EUS and performance status strata. Conclusions: Long-term survival was similar for both arms and did not appear superior to results achieved with other standard regimens.

62 RADIOLOGY AND NUCLEAR MEDICINE↗
NASA NTRS2002

Cirrus Parcel Model Comparison Phase 2

The Cirrus Parcel Model Comparison (CPMC) project, a project of the GEWEX Cloud System Study Working Group on cirrus clouds (GCSS WG2), is an international effort to advance our knowledge of numerical simulations of cirrus cloud initiation. This project was done in two phases. In Phase 1 of CPMC, the critical components determining the predicted cloud microphysical properties were identified using parcel models in which the aerosol and ice crystal size distributions are explicitly resolved, the formulation of the homogeneous freezing of aqueous solution droplets, especially the gradient of nucleation rate with respect to solution concentration; aerosol growth modeling; and the mass accommodation coefficient of water vapor on ice surface (the deposition coefficient). In Phase 1, all simulations were conducted using a given background aerosol distribution. To complete the comparison study, participant model responses to a range of background aerosol distributions are investigated in Phase 2.

Lin, Ruei-Fong↗